Medigen License to C-TAP

In July 2023, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool signed a worldwide license with Medigen Vaccine Biologics Corp. (“Medigen”) for a COVID-19 vaccine based on the COVID-19 spike protein sequence that Medigen licensed from the US National Institutes of Health (NIH). This is the first transparent, global, non-exclusive license for a COVID-19 vaccine and the first health technology developed by a private company and included in C-TAP.

Technology offered: Chinese Hamster Ovary (CHO) cell-derived spike protein (subunit) COVID-19 vaccine

Technology holder: Medigen Vaccine Biologics Corp.

License: Worldwide, non-exclusive and transparent /publicly available license available here

C-TAP categorization after WHO technical pre-assessment: Category IV

Description of the technology: The vaccine is formulated with 1. The Dynavax CPG 1018 adjuvant that Medigen procures from Dynavax, and: 2. AlOH3 which Medigen procures from Croda Health Care. The vaccine is produced in the CHO cell system using the cell line obtained from Thermo Fisher. The vaccine is formulated in 0.5mL liquid, to be administered by  intra muscular injection. It can be stored at 2- 8o C for at least 12 months.

The aim of this license is to ensure equitable access to a COVID-19 vaccine worldwide. The agreement covers all patents and know-how relevant to the development, registration and production of the vaccine. This is the first transparent, global, non-exclusive license for a COVID-19 vaccine and the first technology developed by a private company and included in C-TAP. 

The vaccine has been tested in multiple studies in specific population groups and results have been published in various journals. 

C-TAP invites interested manufacturers based anywhere in the world to express their interest in obtaining a sublicence by submitting a single email to C-TAPvaccines@medicinespatentpool.org